Oral bioavailability of low dose (20 mg) 'home-made' etoposide capsules

Clinical Drug Investigation

Volumn 12, Issue 6, 1996, Pages 298-307

  Jonkman De Vries, J D ^a   Herben, V M M ^a,b   Van Tellingen, O ^b   Dubbelman, A C ^b   Ten Bokkel Huinink, W W ^b   Rodenhuis, S ^b   Bult, A ^c   Beijnen, J H ^a,b,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; LUBRICATING AGENT; SILICON DIOXIDE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; FEMALE; GASTROINTESTINAL ABSORPTION; HOSPITAL PHARMACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICROCAPSULE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0029972150     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199612060-00003     Document Type: Article

References (28)

1. Slevin ML. Low-dose oral etoposide: a new role for an old drug [editorial]? J Clin Oncol 1990; 8: 1607-9
2. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989; 7: 1333-40
3. Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 1987; 12: 223-52
4. Thompson DS, Hainsworth JD, Hande KR, et al. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. J Clin Oncol 1993; 11: 1322-8
5. Clark PI, Joel SP, Slevin ML. A pharmacokinetic hypothesis for the clinical efficacy of etoposide in small cell lung cancer. Proc Am Assoc Clin Oncol 1989; 8: 66
6. Slevin ML, Joel SP. Prolonged oral etoposide in small cell lung cancer [editorial]. Ann Oncol 1993; 4: 529-32
7. Herben VMM, Ten Bokkel Huinink WW, Rodenhuis S, et al. Phase I and pharmacokinetic study of topotecan in combination with oral etoposide. Eur J Cancer 1995; 31A Suppl. 5: S196
8. Herben VMM, Ten Bokkel Huinink WW, Rodenhuis S, et al. Phase I and pharmacokinetic study of topotecan in combination with oral etoposide. Eur J Cancer 1996; 7 Suppl. 1: 133
9. Kozelsky TK, Bonner JA. Sequence-dependent interaction of etoposide and topotecan. Proc Am Assoc Cancer Res 1995; 36: 293
10. Danks MK. Translocation of topoisomerase I from nuclei to cytoplasm of anaplastic astrocytoma cells by topotecan or VP-16. Proc Am Assoc Cancer Res 1995; 36: 450
11. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic daily administration of oral etoposide - a phase I study. J Clin Oncol 1989; 7: 396-401
12. Cavalli F, Zucchetti M, Gentili D, et al. Phase I and clinical pharmacological evaluation of daily oral etoposide (VP16). Proc ASCO 1992; 11: 109
13. Marzola M, Zucchetti M, Colombo N, et al. Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol 1993; 4: 517-9
14. Van Warmerdam LJC, Verweij J, Schellens JHM, et al. Pharmacokinetics and pharmacodynamics of topotecan administered in a daily times five regimen every three weeks. Cancer Chemother Pharmacol 1995; 35: 237-45
15. Anonymous. Uniformity tests: dissolution test for solid oral dosage forms. European Pharmacopeia. 2nd ed. 225-225b; 225d-225g, Sdu Uitgeverij, 's-Gravenhage, The Netherlands, 1983
16. Gibaldi M, Perrier D. Pharmacokinetics (revised and expanded). 2nd ed. New York: Marcel Dekker Inc., 1982; 409-17
17. Sinkule JA, Evans WE. High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection. J Pharm Sci 1984; 73: 164-86
18. Jonkman-de Vries JD, Rosing H, Van Tellingen O, et al. Pharmacokinetics of etoposide after oral and intravenous administration in patients with gastric carcinoma. Clin Drug Invest 1995; 10: 86-95
19. Hakata T, Ijima M, Kimura S, et al. Effects of bases and additives on release of carbon dioxide from effervescent suppositories. Chem Pharm Bull 1993; 41: 351-6
20. Dal Zotto M, Realdon N, Ragazzi E, et al. Effects of two different kinds of silicium dioxide on release of drugs from suppositories: benzydamine hydrochloride. Farmaco 1991; 46: 699-711
21. Bueno L, Fioramonti J. Action of opiates on gastrointestinal function. Baillieres Clin Gastroenterol 1988; 2: 123-9
22. Wood M. Pharmacokinetic drug interactions in anaesthetic practice. Clin Pharmacokinet 1991; 21: 285-307
23. Rowland M, Tozer T. Clinical pharmacokinetics, concepts and applications. 2nd ed. Philadelphia: Lea & Febiger, 1989: 113-30
24. Gibaldi M, Perrier D. Pharmacokinetics (revised and expanded). 2nd ed. New York: Marcel Dekker Inc., 1982; 34-5
25. Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993; 11: 374-7
26. Bernards JA, Bouman LN. Fysiologie van de mens, vijfde, herziene druk. Utrecht/Antwerpen: Bohn, Scheltema & Holkema, 1988: 388-93
27. Beijnen JH, Holthuis JJM, Kerkdijk HG, et al. Degradation kinetics of etoposide in aqueous solution. Int J Pharm 1988; 41: 169-78
28. Shah JC, Chen JR, Chow D. Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. Pharm Res 1989; 6: 408-12